多形性胶质母细胞瘤的放射免疫治疗 - 现状与展望。
Radioimmunotherapy of glioblastoma multiforme - Current status and future prospects.
机构信息
Cancer Research Institute, University of South Australia, Adelaide, SA, 5001, Australia.
Cancer Research Institute, University of South Australia, Adelaide, SA, 5001, Australia; Faculty of Informatics and Science, University of Oradea, Oradea, 410087, Romania.
出版信息
Crit Rev Oncol Hematol. 2021 Jul;163:103395. doi: 10.1016/j.critrevonc.2021.103395. Epub 2021 Jun 10.
Glioblastoma multiforme (GBM) or grade IV astrocytoma is the most diagnosed form of primary brain tumours in adults. Radioimmunotherapy (RIT), mostly in combination with conventional therapies, is presented in the current review as a therapeutic strategy of high potential in the management of GBM. A systematic literature search was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) to identify clinical studies that employed a form of radioimmunotherapy using alpha- or beta-emitting radioisotopes. The available literature on RIT in GBM and high-grade gliomas is presented and discussed. The results suggest that this promising treatment approach merits further investigation in future clinical studies.
多形性胶质母细胞瘤（GBM）或 4 级星形细胞瘤是成年人中最常见的原发性脑肿瘤。放射免疫疗法（RIT），主要与常规疗法联合使用，在目前的综述中作为一种具有高潜力的治疗策略，用于 GBM 的治疗。根据系统评价和荟萃分析的首选报告项目（PRISMA）进行了系统的文献检索，以确定使用α或β发射放射性同位素的放射免疫疗法的临床研究。介绍和讨论了 RIT 在 GBM 和高级别胶质瘤中的现有文献。结果表明，这种有前途的治疗方法值得在未来的临床研究中进一步研究。
Zotero 插件